Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals
--------------------------------------------------------------------
Source: South China Morning Post
Published: 2026-03-01 15:00 UTC+10:00
Section: Eli Lilly
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Asia, China, Financial Markets, Drugs, Business & Economy, Asia Pacific
--------------------------------------------------------------------
Snippet:
Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures
--------------------------------------------------------------------